Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Skin Irritation Study of Tapinarof Cream in Healthy Japanese Subjects
NCT02637206Phase 1Completed
- Sponsor
- GSK
- Start
- Oct 2015
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of tapinarof in atopic dermatitis (AD) and plaque psoriasis (2 arms), sponsored by GSK. Primary endpoints: Positive rate of skin irritability as assessed by simple-patch test at Day 4, Positive rate of photo-urticaria reaction as assessed by photo patch test at Day 2 and 3 more. Started Oct 2015; status: completed.
02
Drugs
tapinarof
03
Conditions
atopic dermatitis (AD)plaque psoriasis
Beyond the preview
Go deeper on NCT02637206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02637206.